

## NEWS RELEASE

### **Licensing, supply and distribution of Wafesil™, sublingual sildenafil wafer, in China**

- ✓ **Yiling Pharmaceutical Ltd. granted an exclusive licence to register and distribute Wafesil™, for treatment of male erectile dysfunction, in China**
- ✓ **The agreement marks iX Biopharma's entry into the China pharmaceutical market**

**Singapore, 27 April 2020** – Specialty pharmaceutical company **iX Biopharma Ltd** (SGX:42C) (“iX Biopharma”) is pleased to announce that it has entered into a licensing agreement with Yiling Pharmaceutical Ltd. (“Yiling”) for the licensing, supply and distribution of Wafesil™, a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China (the “Wafesil China Agreement”).

Under the Wafesil China Agreement, Yiling will be granted an exclusive license to market and distribute Wafesil™ in China after it obtains marketing authorisation in the name of iX Biopharma in China. iX Biopharma will manufacture and supply Wafesil™ to Yiling at a supply price agreed between the parties. The initial term of the agreement is 10 years.

Yiling will pay to iX Biopharma an upfront and certain milestone payments prior to the commercialisation of Wafesil™. The milestone payments will be made upon the completion of bioequivalence studies and on the first commercial supply of wafers by iX Biopharma to Yiling. In addition, Yiling has agreed to fund any bioequivalence studies and regulatory submissions necessary for the registration of the product in China.

By partnering with Yiling, iX Biopharma will be able to access the market through Yiling's sales and distribution network covering 100,000 medical and health institutions and over 300,000 pharmacies in China. Due to its novel and superior dosage form, Yiling estimates the first five years of sales in China for Wafesil™ to be around RMB 700 to 800 million.

Wafesil™ is a new dose form of sildenafil, formulated using iX Biopharma's patented sublingual drug delivery technology, WaferiX®. It is a registered pharmaceutical medicine in Australia and an application has been made to the European Medicines Agency for marketing authorisation in Europe.

**Mr Zhao Shaohua, President of Yiling Pharmaceutical Ltd said:** *“There is a significant and growing market for sildenafil in China. We see huge potential in Wafesil™, a quality drug imported from Australia. This is because Wafesil™ is patented with a novel sublingual delivery, and has the potential for better absorption and faster onset of therapeutic action.”*

**Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma said:** *“We are delighted that in Yiling, we have a strong partner for our inaugural entry into the China pharmaceutical drug market. We have confidence in Yiling's regulatory expertise to successfully register Wafesil™ in China, after which we will be able to leverage on their established sales distribution network covering hospitals and pharmacies across all of China. Like Yiling, we are excited about the sales potential of Wafesil™ in the Chinese market due to its novel, superior dosage form achieved using the WaferiX delivery technology.”*

Wafesil™ is the first drug of iX Biopharma's drug pipeline to be out-licensed. In addition to Wafesil™, iX Biopharma has a rich pipeline of other drugs formulated with the WaferiX® drug delivery platform technology that have the potential to be partnered for global markets.

### **About iX Biopharma Ltd**

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Stock Exchange of Singapore (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.

iX Biopharma's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma's drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the world's first freeze-dried sublingual medicinal cannabis wafer.

The Group's nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products through more than 250 pharmacies and health food shops in Australia and online.

### **About Yiling Pharmaceutical Ltd.**

Yiling Pharmaceutical Ltd. is a subsidiary of Shijiazhuang Yiling Pharmaceutical Co. Ltd., a public company listed on the Shenzhen Stock Exchange. Shijiazhuang Yiling Pharmaceutical Co. Ltd. has been designated a national key high-tech enterprise in the top 20 China pharma list. It operates an integrated business covering R&D, production and distribution. It has developed a broad range of drugs including traditional Chinese medicines (Chinese patent drugs) and chemical pharmaceutical drugs in therapeutic areas such as cardiovascular, respiratory, oncology and diabetes. Its distribution business includes direct sales to hospitals, commercial allocation, and terminal distribution, and products are sold through its network covering over 100,000 medical and health institutions and over 300,000 pharmacies in China. In 2018, its revenue was approximately RMB 4.81 billion.

#### **Contact for media:**

**Dr Janakan Krishnarajah**

Chief Operating Officer and Chief Medical Officer

T: +65 6235 2270

E: [j.krishnarajah@ixbiopharma.com](mailto:j.krishnarajah@ixbiopharma.com)

**Eva Tan**

Director, Corporate and Commercial Strategy

T: +65 6235 3212

E: [eva.tan@ixbiopharma.com](mailto:eva.tan@ixbiopharma.com)

#### **Investor Relations:**

**Kamal Samuel/James Bywater/Jonathan Wee**

T: +65 6438 2990

E: [Tech@financialpr.com.sg](mailto:Tech@financialpr.com.sg)

---

This announcement has been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch ("Sponsor") in accordance with Rule 226(2)(b) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Yee Chia Hsing, Head, Catalist. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.